Evidence map›Paper›PMID 23036023›Full record

ArticleCurrent Alzheimer research2013

BACE1 levels by APOE genotype in non-demented and Alzheimer's post-mortem brains.

Boris Decourt, Amanda Gonzales, Thomas G Beach, Michael Malek-Ahmadi, Aaron Walker, Lucia Sue, Douglas G Walker, Marwan N Sabbagh

Open access · bronzeAbstract read
In one paragraph

Article in Current Alzheimer research, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.5field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 12 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Arizona Study of Aging and Neurodegenerative Disorders and Brain and Body Donation Program.Neuropathology : official journal of the Japanese Society of Neuropathology · 2015
    Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Boris DecourtHaldeman Laboratory of Molecular Diagnostics and Therapeutics, Banner Sun Health Research Institute, Sun City, AZ 85351, USA.
Amanda Gonzales
Thomas G Beach
Michael Malek-Ahmadi
Aaron Walker
Lucia Sue
Douglas G Walker
Marwan N Sabbagh
Banner Sun Health Research Institute · US

Funding

Research Education ComponentP30AG019610 · NIA · SUN HEALTH RESEARCH INSTITUTE · PI GONZALEZ HERNANDEZ, GRACIELA · 2001 to 2020
$32.5M
Study on Thalidomide as BACE1 inhibitor in Alzhiemer's diseaseR01AG034155 · NIA · BANNER SUN HEALTH RESEARCH INSTITUTE · PI SABBAGH, MARWAN NOEL · 2009 to 2010
$1.7M
NIA NIH HHS 5P30AG019610-12NIA NIH HHS P30 AG019610NIA NIH HHS P30AG019610-09NIA NIH HHS P30 AG19610NIA NIH HHS R01 AG034155NIA NIH HHS R01AG034155
6 · The paper itself

Abstract

The APOE genotype is a known susceptibility factor for Alzheimer's disease (AD). It is apparent that the presence of the APOE ε40 allele increases the risk for developing AD, lowers the age of onset in AD, and may influence the pathological burden seen in AD. In this study, we asked whether BACE1 levels differ by APOE genotype in the AD and non-demented (ND) brain. We isolated mid-frontal cortex (MFC) and mid-temporal cortex (MTC) from post-mortem ND and AD subjects that were APOE ε3/3, ε3/4, ε4/4 carriers. All AD subjects met NINDS-ADRDA and NIA-Reagan criteria for a diagnosis of AD. The MFC and MTC were homogenized and the lysates underwent ELISA and Western blotting for BACE1. The ELISA revealed that total BACE1 levels were lower in the MFC of AD compared to ND subjects. Furthermore, in APOE ε4 carriers BACE1 levels were lower than ε3/3 carriers in the ND frontal cortex. No difference in BACE1 levels was observed in AD MFC and in ND and AD MTC tissues. The ELISA results were confirmed by Western blotting. Our data suggest that brain BACEl levels may be influenced by the apolipoprotein E genotype before the onset of AD, providing an alternative explanation for the lower amyloid beta 42 levels in CSF in ND and AD subjects.

Indexed as

AgedAged, 80 and overAlzheimer DiseaseAmyloid Precursor Protein SecretasesApolipoproteins EAspartic Acid EndopeptidasesAutopsyBlotting, WesternBrainEnzyme-Linked Immunosorbent AssayFemaleGenetic Predisposition to DiseaseGenotypeHumansMalePolymerase Chain ReactionAmyloid Precursor Protein SecretasesApolipoproteins EAspartic Acid EndopeptidasesBACE1 protein, human

Identifiers

PMID23036023
PMCPMC4104947
OpenAlexW2130875757

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.